Excel Venture Management

InfoBionic, Inc., founded in 2011 and based in Lowell, Massachusetts, specializes in remote patient monitoring and cardiac diagnostic services through its cloud-based platform, MoMe™. The MoMe System is designed to enhance the detection of cardiac arrhythmias, allowing healthcare providers to access vital patient data anytime and anywhere. By replicating in-hospital telemetry data, the platform streams continuous electrocardiogram, respiration, and motion data to the cloud for real-time analysis. This innovation aims to improve clinical efficiency and patient care, enabling physicians to monitor and treat cardiac complications effectively.

Ayogo Health Inc. is a Vancouver-based company that specializes in developing applications and games aimed at managing chronic health conditions and improving patient adherence. Established in 2008, Ayogo employs behavioral psychology and social gaming principles to enhance health outcomes, serving a diverse clientele that includes insurers, healthcare providers, and pharmaceutical companies. The company's flagship product, GoodLife, is a customizable platform featuring gamification elements, incentives, and social interaction, while its suite of Alternate Reality Games integrates online and real-world experiences to facilitate learning. Ayogo's platform is designed to tailor content and support to individual psychosocial factors, promoting patient engagement by fostering activation and adherence to therapy. With a collaborative approach involving patients and clients, Ayogo emphasizes thoughtful innovation within its creative studio environment.

Neosensory, Inc. is a company that specializes in developing wearable devices aimed at enhancing sensory perception for individuals. Founded in 2015 and based in San Mateo, California, Neosensory offers products such as Buzz, which utilizes vision-to-touch sensory substitution technology to assist blind individuals. The company focuses on transmitting various data streams to the brain through the sense of touch, leveraging the skin's potential for information delivery. Their innovative approach includes building hearing assistive technology that allows users to perceive sound through vibrations on the skin. Neosensory also provides a companion application for its products, enhancing the user experience and accessibility of information.

ClearDATA Networks is a company that specializes in cloud computing and information security services tailored for the healthcare industry. Based in Austin, Texas, ClearDATA offers a HITRUST-certified cloud platform designed to protect sensitive patient data and support critical healthcare applications across major public cloud environments. Its comprehensive solutions include cloud security posture management and managed detection and response services, ensuring compliance with industry regulations and safeguarding personal health information. By providing robust data management capabilities and multi-cloud expertise, ClearDATA empowers healthcare organizations to scale their IT infrastructure effectively, allowing them to focus on enhancing healthcare delivery and improving patient outcomes.

Openwater is a San Francisco-based startup founded in 2016 that focuses on developing advanced medical technology aimed at diagnosing and treating diseases at the cellular level. The company has created a wearable device that leverages novel optoelectronic technology to offer high-resolution imaging capabilities, effectively replacing traditional MRI methods. By utilizing LCDs with small pixels, Openwater's device generates holographic images that minimize scattering and achieve MRI-like resolution. This innovation enables physicians to diagnose and treat diseases by targeting individual cells while preserving the surrounding tissue, thereby enhancing the precision and effectiveness of medical interventions.

InfoBionic, Inc., founded in 2011 and based in Lowell, Massachusetts, specializes in remote patient monitoring and cardiac diagnostic services through its cloud-based platform, MoMe™. The MoMe System is designed to enhance the detection of cardiac arrhythmias, allowing healthcare providers to access vital patient data anytime and anywhere. By replicating in-hospital telemetry data, the platform streams continuous electrocardiogram, respiration, and motion data to the cloud for real-time analysis. This innovation aims to improve clinical efficiency and patient care, enabling physicians to monitor and treat cardiac complications effectively.

Openwater is a San Francisco-based startup founded in 2016 that focuses on developing advanced medical technology aimed at diagnosing and treating diseases at the cellular level. The company has created a wearable device that leverages novel optoelectronic technology to offer high-resolution imaging capabilities, effectively replacing traditional MRI methods. By utilizing LCDs with small pixels, Openwater's device generates holographic images that minimize scattering and achieve MRI-like resolution. This innovation enables physicians to diagnose and treat diseases by targeting individual cells while preserving the surrounding tissue, thereby enhancing the precision and effectiveness of medical interventions.

ClearDATA Networks is a company that specializes in cloud computing and information security services tailored for the healthcare industry. Based in Austin, Texas, ClearDATA offers a HITRUST-certified cloud platform designed to protect sensitive patient data and support critical healthcare applications across major public cloud environments. Its comprehensive solutions include cloud security posture management and managed detection and response services, ensuring compliance with industry regulations and safeguarding personal health information. By providing robust data management capabilities and multi-cloud expertise, ClearDATA empowers healthcare organizations to scale their IT infrastructure effectively, allowing them to focus on enhancing healthcare delivery and improving patient outcomes.

Oculus Health, Inc. operates a chronic care management platform that connects healthcare providers with patients and caregivers. Founded in 2014 and based in Irving, Texas, the company offers a range of services including access to personalized care plans, online and phone support from medical assistants, and real-time health data monitoring. Its platform integrates information from various healthcare sources, such as hospitals and laboratories, to facilitate seamless communication among care teams. Oculus Health also provides tools for remote monitoring, health record management, and patient engagement, aimed at improving patient outcomes and care adherence. By empowering individuals to manage their health proactively, the company seeks to enhance the overall experience of both patients and healthcare providers in a rapidly evolving healthcare landscape.

Qstream, Inc. is a software as a service company that offers a mobile sales acceleration platform designed to enhance job proficiency and drive behavioral change within sales teams. Founded in 2008 and headquartered in Burlington, Massachusetts, Qstream serves various industries, including technology, financial services, and life sciences. The company specializes in micro-learning and analytics, aiming to improve the effectiveness of sales personnel through measurable outcomes. Qstream also has engineering facilities in Dublin, Ireland, and Hood River, Oregon, along with sales headquarters in Maidenhead, United Kingdom, and an office in San Francisco.

Foodsmart is a digital nutrition platform focused on enhancing health outcomes through personalized dietary recommendations. The company aims to support individuals dealing with chronic diseases and food insecurity by collaborating with health plans and healthcare providers. Its online telehealth application offers real-time guidance across various settings, including homes, workplaces, grocery stores, and restaurants. This comprehensive approach enables users to make healthier food choices and select recipes that can mitigate chronic health issues, thereby promoting overall well-being. By providing access to affordable and tailored healthy eating options, Foodsmart strives to empower individuals to improve their nutrition and health.

InfoBionic, Inc., founded in 2011 and based in Lowell, Massachusetts, specializes in remote patient monitoring and cardiac diagnostic services through its cloud-based platform, MoMe™. The MoMe System is designed to enhance the detection of cardiac arrhythmias, allowing healthcare providers to access vital patient data anytime and anywhere. By replicating in-hospital telemetry data, the platform streams continuous electrocardiogram, respiration, and motion data to the cloud for real-time analysis. This innovation aims to improve clinical efficiency and patient care, enabling physicians to monitor and treat cardiac complications effectively.

N-of-One, Inc. is a molecular decision support company that specializes in the interpretation of molecular test results for cancer care. It provides clinicians with detailed insights into the biological relevance of diseases, clinical evidence, associated therapies, and references. The company interprets next-generation sequencing (NGS) data from solid and hematological tumors, as well as circulating tumor cells and DNA. N-of-One delivers a clinical interpretation report called PrecisionInsights, which covers 15-20 gene NGS panels, summarizing clinical and scientific evidence for each biomarker relevant to specific cancer subtypes and listing potential therapeutic options. Additionally, it offers TRIALMATCH, a solution for matching patients to suitable clinical trials based on their individual profiles. N-of-One serves various stakeholders, including commercial and hospital laboratories and precision medicine programs. Founded in 2007 and based in Lexington, Massachusetts, N-of-One operates as a subsidiary of QIAGEN N.V. since January 2019.

Welldoc, Inc. specializes in developing technology solutions for chronic disease management, focusing primarily on diabetes care. Its flagship product, the DiabetesManager platform, allows patients and healthcare providers to coordinate care effectively, promoting self-management and adherence to treatment. This platform includes features such as personalized coaching, medication reminders, out-of-bound alerts, and cloud-based analytics for tracking health metrics. Additionally, Welldoc offers BlueStar, a mobile prescription therapy that provides real-time guidance for diabetes management and clinical decision support for healthcare professionals. The company collaborates with various stakeholders, including payors, employers, pharmaceutical firms, and healthcare systems, to ensure its solutions integrate seamlessly into existing workflows. Founded in 2005 and based in Baltimore, Maryland, with additional offices in Wilmington, Delaware, and Bengaluru, India, Welldoc aims to transform digital health management through innovative technology and artificial intelligence.

ClearDATA Networks is a company that specializes in cloud computing and information security services tailored for the healthcare industry. Based in Austin, Texas, ClearDATA offers a HITRUST-certified cloud platform designed to protect sensitive patient data and support critical healthcare applications across major public cloud environments. Its comprehensive solutions include cloud security posture management and managed detection and response services, ensuring compliance with industry regulations and safeguarding personal health information. By providing robust data management capabilities and multi-cloud expertise, ClearDATA empowers healthcare organizations to scale their IT infrastructure effectively, allowing them to focus on enhancing healthcare delivery and improving patient outcomes.

Ayogo Health Inc. is a Vancouver-based company that specializes in developing applications and games aimed at managing chronic health conditions and improving patient adherence. Established in 2008, Ayogo employs behavioral psychology and social gaming principles to enhance health outcomes, serving a diverse clientele that includes insurers, healthcare providers, and pharmaceutical companies. The company's flagship product, GoodLife, is a customizable platform featuring gamification elements, incentives, and social interaction, while its suite of Alternate Reality Games integrates online and real-world experiences to facilitate learning. Ayogo's platform is designed to tailor content and support to individual psychosocial factors, promoting patient engagement by fostering activation and adherence to therapy. With a collaborative approach involving patients and clients, Ayogo emphasizes thoughtful innovation within its creative studio environment.

Orionis Biosciences is a biotechnology company focused on early-stage drug discovery and development, particularly targeting oncology and immunotherapies. Headquartered in Waltham, Massachusetts, with additional research facilities in Ghent, Belgium, the company utilizes a range of innovative technologies to create conditionally active drug modalities aimed at treating diseases with significant unmet medical needs. By inducing molecular proximity and cooperativity, Orionis enhances drug potency and precision, allowing for novel target access. Their approach facilitates the development of a diverse pipeline of drug candidates, including therapies that engage both adaptive and innate immune systems. The company collaborates with strategic partners, including VIB in Belgium, and is supported by a team of seasoned entrepreneurs and scientists, as well as a transatlantic network of investors.

Gemphire Therapeutics, a clinical-stage biopharmaceutical company based in Northville, Michigan, focuses on developing and commercializing therapies for dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company's lead product, gemcabene, is an oral medication designed to lower LDL cholesterol in patients who cannot achieve lipid-lowering goals, even while on maximally tolerated statin therapy. Gemphire has completed three Phase IIb clinical trials for gemcabene, targeting conditions such as homozygous familial hypercholesterolemia, hypercholesterolemia, and severe hypertriglyceridemia. Founded in 2014, the company aims to address unmet needs in cardiometabolic disorders and improve patient outcomes. In late 2019, Gemphire Therapeutics was acquired by NeuroBo Pharmaceuticals in a reverse merger transaction.

Aventura intelligently orchestrates assets, people, and systems to deliver the right information at the right time based on location and credentials. It locates and re-assigns the closest online printer and uniquely manages print routing to make it easier to detect and fix printing failures. Aventura was formed in 2007 and headquartered in Denver, Colorado.

Qstream, Inc. is a software as a service company that offers a mobile sales acceleration platform designed to enhance job proficiency and drive behavioral change within sales teams. Founded in 2008 and headquartered in Burlington, Massachusetts, Qstream serves various industries, including technology, financial services, and life sciences. The company specializes in micro-learning and analytics, aiming to improve the effectiveness of sales personnel through measurable outcomes. Qstream also has engineering facilities in Dublin, Ireland, and Hood River, Oregon, along with sales headquarters in Maidenhead, United Kingdom, and an office in San Francisco.

Foodsmart is a digital nutrition platform focused on enhancing health outcomes through personalized dietary recommendations. The company aims to support individuals dealing with chronic diseases and food insecurity by collaborating with health plans and healthcare providers. Its online telehealth application offers real-time guidance across various settings, including homes, workplaces, grocery stores, and restaurants. This comprehensive approach enables users to make healthier food choices and select recipes that can mitigate chronic health issues, thereby promoting overall well-being. By providing access to affordable and tailored healthy eating options, Foodsmart strives to empower individuals to improve their nutrition and health.

Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, dedicated to developing innovative therapeutics, particularly stabilized cell-permeating alpha-helical peptides, for oncology and other therapeutic areas. The company’s lead product candidate, ALRN-6924, is designed to treat advanced solid tumors and is currently undergoing various clinical trials, including Phase 2a studies for peripheral T-cell lymphoma and advanced solid tumors, as well as Phase 1 trials for acute myeloid leukemia and myelodysplastic syndromes. Aileron Therapeutics also explores next-generation wild type p53 reactivators and has established collaborations with notable institutions such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer to evaluate the effectiveness of ALRN-6924 in combination with other treatments. Founded in 2001 and originally known as Renegade Therapeutics, the company aims to address critical cell functions through its novel approach to modulating protein-protein interactions.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to the discovery and development of biologic therapeutics aimed at treating cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create therapies with unique mechanisms of action that differ from traditional antibody-drug conjugates. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing other candidates, including MT-4019, which targets CD38, and has a partnership with Takeda Pharmaceutical Company to create CD38-targeted therapies for multiple myeloma. The company also collaborates with Vertex Pharmaceuticals to enhance the hematopoietic stem cell transplant process through novel conditioning regimens.

Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, dedicated to developing innovative therapeutics, particularly stabilized cell-permeating alpha-helical peptides, for oncology and other therapeutic areas. The company’s lead product candidate, ALRN-6924, is designed to treat advanced solid tumors and is currently undergoing various clinical trials, including Phase 2a studies for peripheral T-cell lymphoma and advanced solid tumors, as well as Phase 1 trials for acute myeloid leukemia and myelodysplastic syndromes. Aileron Therapeutics also explores next-generation wild type p53 reactivators and has established collaborations with notable institutions such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer to evaluate the effectiveness of ALRN-6924 in combination with other treatments. Founded in 2001 and originally known as Renegade Therapeutics, the company aims to address critical cell functions through its novel approach to modulating protein-protein interactions.

ShapeUp is a provider of corporate wellness solutions based in Providence, Rhode Island. Founded in 2006, the company utilizes a social networking platform to promote employee health and wellness through incentives and gamification. ShapeUp's programs are clinically proven and have reached over 2 million individuals, serving more than 500 employers and health plans across 109 countries. The company's approach focuses on driving positive health outcomes for large populations by integrating social interaction and financial rewards into its wellness initiatives.

PathoGenetiX is developing an automated system for the rapid identification of pathogenic bacterial strains using proprietary Genome Sequence Scanning Technology. The company's approach, which employs a single reagent set to generate genomic bar codes based on bacterial DNA, can cost-effectively identify thousands of strains in a single test from complex samples in three hours. PathoGenetiX is developing its GSS platform for use in genomics research, food and product safety testing, and clinical infectious disease diagnostics, with the initial commercial introduction into the research market planned for 2012.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to the discovery and development of biologic therapeutics aimed at treating cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create therapies with unique mechanisms of action that differ from traditional antibody-drug conjugates. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing other candidates, including MT-4019, which targets CD38, and has a partnership with Takeda Pharmaceutical Company to create CD38-targeted therapies for multiple myeloma. The company also collaborates with Vertex Pharmaceuticals to enhance the hematopoietic stem cell transplant process through novel conditioning regimens.

Aventura intelligently orchestrates assets, people, and systems to deliver the right information at the right time based on location and credentials. It locates and re-assigns the closest online printer and uniquely manages print routing to make it easier to detect and fix printing failures. Aventura was formed in 2007 and headquartered in Denver, Colorado.

ClearDATA Networks is a company that specializes in cloud computing and information security services tailored for the healthcare industry. Based in Austin, Texas, ClearDATA offers a HITRUST-certified cloud platform designed to protect sensitive patient data and support critical healthcare applications across major public cloud environments. Its comprehensive solutions include cloud security posture management and managed detection and response services, ensuring compliance with industry regulations and safeguarding personal health information. By providing robust data management capabilities and multi-cloud expertise, ClearDATA empowers healthcare organizations to scale their IT infrastructure effectively, allowing them to focus on enhancing healthcare delivery and improving patient outcomes.

Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, dedicated to developing innovative therapeutics, particularly stabilized cell-permeating alpha-helical peptides, for oncology and other therapeutic areas. The company’s lead product candidate, ALRN-6924, is designed to treat advanced solid tumors and is currently undergoing various clinical trials, including Phase 2a studies for peripheral T-cell lymphoma and advanced solid tumors, as well as Phase 1 trials for acute myeloid leukemia and myelodysplastic syndromes. Aileron Therapeutics also explores next-generation wild type p53 reactivators and has established collaborations with notable institutions such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer to evaluate the effectiveness of ALRN-6924 in combination with other treatments. Founded in 2001 and originally known as Renegade Therapeutics, the company aims to address critical cell functions through its novel approach to modulating protein-protein interactions.

Activate Networks, Inc. is a network analytics company that specializes in mapping, analyzing, and activating social networks to enhance commercial and organizational outcomes. By utilizing its proprietary RealConnect™ platform, the company provides analytics products that help organizations unlock the value of their existing social networks, including those of customers, prospects, voters, and employees. This approach leverages readily available data to generate actionable insights that can significantly influence marketing strategies, health-behavior initiatives, talent management, and innovation across various sectors, such as healthcare, technology, political campaigns, and professional services. Through its technology, Activate Networks empowers users to understand the key connections that drive results in their respective fields.

Cleveland HeartLab, Inc. is a specialty clinical laboratory dedicated to the prevention and management of cardiovascular disease (CVD). The company specializes in novel biomarker technologies and develops proprietary diagnostic tests aimed at improving the early identification of individuals at risk for CVD. Cleveland HeartLab offers a range of clinical laboratory services, including an inflammatory panel for CVD, advanced CVD risk profiles, and lipid panels. By focusing on innovative molecular biomarker technologies, the company seeks to enhance the management and reduction of inflammation, ultimately contributing to better cardiovascular health outcomes.

IlluminOss Medical, Inc. is a commercial-stage medical device company that specializes in minimally invasive technology for fracture repair and stabilization. The company has developed a unique system that uses a light-curable polymer within an expandable balloon to create a patient-conforming intramedullary implant, facilitating effective bone stabilization. This innovative approach is particularly beneficial for patients with osteoporotic or compromised bone, providing a tailored solution for orthopedic challenges. The IlluminOss system is CE-marked and FDA-cleared for various anatomical sites, with additional indications under review. By focusing on the design and marketing of orthopedic fracture repair products, IlluminOss aims to offer clinicians a rapid and customized method for stabilizing bone fractures.

PathoGenetiX is developing an automated system for the rapid identification of pathogenic bacterial strains using proprietary Genome Sequence Scanning Technology. The company's approach, which employs a single reagent set to generate genomic bar codes based on bacterial DNA, can cost-effectively identify thousands of strains in a single test from complex samples in three hours. PathoGenetiX is developing its GSS platform for use in genomics research, food and product safety testing, and clinical infectious disease diagnostics, with the initial commercial introduction into the research market planned for 2012.

MedVentive specializes in technology solutions that enhance the quality and cost-effectiveness of healthcare delivery. Founded by physicians in 1997, the company focuses on providing intervention and information solutions for healthcare delivery networks, payers, and employer coalitions. Its offerings include quality management, registries, pharmacy management, clinical integration, and managed care performance. Additionally, MedVentive provides point-of-care decision support and a pay-for-performance solution that calculates and tracks clinical measures, delivering tailored intervention recommendations for patients. Through these innovative tools, MedVentive aims to facilitate meaningful improvements in healthcare outcomes and reduce overall costs.

Aventura intelligently orchestrates assets, people, and systems to deliver the right information at the right time based on location and credentials. It locates and re-assigns the closest online printer and uniquely manages print routing to make it easier to detect and fix printing failures. Aventura was formed in 2007 and headquartered in Denver, Colorado.

Lantos Technologies, Inc. specializes in 3D digital ear scanning technology, which facilitates the design of personalized in-ear devices such as headphones, musicians' monitors, hearing aids, and noise protection solutions. The company's AURA 3D ear scanning system is the only FDA-cleared solution of its kind, providing accurate and minimally invasive mapping of the ear canal. This technology collects multiple data points to create detailed digital maps of the ear, improving the comfort, sound quality, and performance of custom products. By enhancing clinical efficiency and enabling faster turnaround times for custom devices, Lantos Technologies aims to deliver better outcomes for patients and audiologists alike. Founded in 2009 and based in Derry, New Hampshire, the company was previously known as Lantos 2.0 Inc. before rebranding in December 2020.

Cleveland HeartLab, Inc. is a specialty clinical laboratory dedicated to the prevention and management of cardiovascular disease (CVD). The company specializes in novel biomarker technologies and develops proprietary diagnostic tests aimed at improving the early identification of individuals at risk for CVD. Cleveland HeartLab offers a range of clinical laboratory services, including an inflammatory panel for CVD, advanced CVD risk profiles, and lipid panels. By focusing on innovative molecular biomarker technologies, the company seeks to enhance the management and reduction of inflammation, ultimately contributing to better cardiovascular health outcomes.

PathoGenetiX is developing an automated system for the rapid identification of pathogenic bacterial strains using proprietary Genome Sequence Scanning Technology. The company's approach, which employs a single reagent set to generate genomic bar codes based on bacterial DNA, can cost-effectively identify thousands of strains in a single test from complex samples in three hours. PathoGenetiX is developing its GSS platform for use in genomics research, food and product safety testing, and clinical infectious disease diagnostics, with the initial commercial introduction into the research market planned for 2012.

NanoMR specializes in the development of blood diagnostic devices, focusing on the rapid isolation of rare cells from complex biological samples at concentrations as low as one cell per milliliter. The company's innovative immunomagnetic capture system allows for the simultaneous targeting of multiple cell types, enabling the efficient extraction of bacteria and fungi in cases of bloodstream infections, as well as specific cells such as circulating tumor or fetal cells. This process is completed in under 30 minutes, significantly enhancing the speed and accuracy of diagnostics in clinical settings.

SpringLeaf Therapeutics (formerly known as Entra Pharmaceuticals, Inc.) is creating innovative therapeutic modalities to address serious disease and elevate the quality of care for patients. SpringLeaf's technology is based on convergent science and is designed to enable and differentiate therapeutics. SpringLeaf was founded based on breakthrough science at MIT and is backed by leading investors including Flybridge Capital Partners and North Bridge Venture Partners.

Catch.com (formerly Snaptic) is a market leader for Android smartphones and tablets. Millions have downloaded our mobile apps, including Catch Notes, AK Notepad and Compass. Our mobile apps also run on iOS and the web, and we are just getting started. Catch.com was founded in 2008 and is on the cusp of a seismic shift driven by growth in smartphone use -- reinventing how people interact, collaborate and discover what’s important to them.

Lantos Technologies, Inc. specializes in 3D digital ear scanning technology, which facilitates the design of personalized in-ear devices such as headphones, musicians' monitors, hearing aids, and noise protection solutions. The company's AURA 3D ear scanning system is the only FDA-cleared solution of its kind, providing accurate and minimally invasive mapping of the ear canal. This technology collects multiple data points to create detailed digital maps of the ear, improving the comfort, sound quality, and performance of custom products. By enhancing clinical efficiency and enabling faster turnaround times for custom devices, Lantos Technologies aims to deliver better outcomes for patients and audiologists alike. Founded in 2009 and based in Derry, New Hampshire, the company was previously known as Lantos 2.0 Inc. before rebranding in December 2020.

ShapeUp is a provider of corporate wellness solutions based in Providence, Rhode Island. Founded in 2006, the company utilizes a social networking platform to promote employee health and wellness through incentives and gamification. ShapeUp's programs are clinically proven and have reached over 2 million individuals, serving more than 500 employers and health plans across 109 countries. The company's approach focuses on driving positive health outcomes for large populations by integrating social interaction and financial rewards into its wellness initiatives.

Viridos is a company that develops and commercializes genomic-driven solutions aimed at tackling global energy and environmental issues. It specializes in synthesizing and programming DNA to create and utilize technologies in synthetic genomics. The company designs and develops microbes for various industrial processes and environmental applications, including microbial cultivation technologies that identify novel microorganisms and new genes. Additionally, Viridos focuses on enhancing biofuel production, utilizing photosynthetic organisms to generate value-added products from sunlight and carbon dioxide, and improving the recovery rates of subsurface hydrocarbons. Its innovations also extend to the development of high-yield, disease-resistant feedstocks. Through these efforts, Viridos contributes to the production of energy, chemicals, and pharmaceuticals, while also promoting carbon sequestration and environmental remediation.

Catch.com (formerly Snaptic) is a market leader for Android smartphones and tablets. Millions have downloaded our mobile apps, including Catch Notes, AK Notepad and Compass. Our mobile apps also run on iOS and the web, and we are just getting started. Catch.com was founded in 2008 and is on the cusp of a seismic shift driven by growth in smartphone use -- reinventing how people interact, collaborate and discover what’s important to them.

Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel antibiotics to combat serious multidrug-resistant infections. Its primary product candidate, Xerava (eravacycline), is a synthetic fluorocycline designed for intravenous use as a first-line treatment for multidrug-resistant infections, particularly those caused by Gram-negative bacteria. The company has conducted Phase III clinical trials, including IGNITE1 and IGNITE4, to evaluate Xerava's safety and efficacy for treating complicated intra-abdominal infections. In addition to Xerava, Tetraphase is advancing other product candidates, such as TP-271, which targets respiratory diseases caused by antibiotic-resistant pathogens, and TP-6076, aimed at treating multidrug-resistant Gram-negative infections. The company holds a licensing agreement with Everest Medicines Limited to develop and commercialize Xerava in various Asian markets. Founded in 2006 and headquartered in Watertown, Massachusetts, Tetraphase Pharmaceuticals is a subsidiary of La Jolla Pharmaceutical Company.

IntraPace, Inc. specializes in the development and marketing of implantable devices aimed at treating obesity. Founded in 2001 and located in Mountain View, California, the company has created the abiliti system, which stimulates a satiety response to facilitate weight loss. This innovative device is based on technology commonly used in cardiac pacemakers and defibrillators, allowing for implantation through standard laparoscopic methods. Notably, the abiliti system does not alter the digestive system's anatomy and imposes no restrictions on a patient's dietary intake, making it a versatile option for individuals seeking weight management solutions.

TransMedics Group Inc is a commercial-stage medical technology company focused on transforming organ transplant therapy for patients with end-stage organ failure. The company has developed the Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system designed to overcome the limitations of traditional cold storage methods for organ preservation. By replicating near-physiologic conditions for donor organs outside the human body, the OCS enhances the viability and functionality of organs prior to transplantation, thereby improving clinical outcomes. TransMedics aims to increase heart and lung transplant volumes while reducing learning curves for healthcare providers, ultimately addressing critical needs in organ transplantation.

Saladax Biomedical, Inc. is a precision medicine company based in Bethlehem, Pennsylvania, specializing in the development and commercialization of diagnostic blood tests designed to enhance personalized medicine. The company focuses on adherence testing for psychiatrists and chemotherapeutic drug monitoring for oncologists. Its product line, known as MyCare, includes tests such as MyCare Psychiatry, which helps determine the appropriate antipsychotic dosage for patients; MyCare Oncology, which optimizes chemotherapy exposure; and MyCare Neurology, for assessing the effects of neurological drugs. Specific tests include My5-FU, MyPaclitaxel, MyDocetaxel, and MyImatinib, which are used to manage treatment for various cancers and conditions. Saladax markets its products through distributors across the Asia Pacific, European Union, Middle East, and North Africa, as well as through direct sales in select regions. With over 15 years of experience, Saladax aims to provide convenient and cost-effective solutions for therapeutic drug monitoring, enabling physicians to tailor drug dosing to individual patient needs.

Biocius Life Sciences, Inc. is a company specializing in drug discovery research, established in 2009 and located in Woburn, Massachusetts. As a subsidiary of BioTrove, Inc., Biocius develops advanced technologies, including high-throughput mass spectrometry systems, to facilitate the drug discovery process. The company's innovative approach aims to enhance efficiency and accuracy in identifying potential therapeutic compounds, contributing to advancements in pharmaceutical research and development.

Virgin Pulse, a subsidiary of Sir Richard Branson's Virgin Group, focuses on developing technology that promotes healthy lifestyle habits among employees. By tailoring its solutions to align with organizational culture, Virgin Pulse enhances the overall well-being experience for users, leading to improved outcomes for both employees and businesses. The brand, established in 1970, is recognized for its commitment to creating exceptional consumer experiences through innovation and quality service. Virgin Pulse aims to foster engagement and support within workplaces, contributing to a healthier workforce and a more productive environment.

MedVentive specializes in technology solutions that enhance the quality and cost-effectiveness of healthcare delivery. Founded by physicians in 1997, the company focuses on providing intervention and information solutions for healthcare delivery networks, payers, and employer coalitions. Its offerings include quality management, registries, pharmacy management, clinical integration, and managed care performance. Additionally, MedVentive provides point-of-care decision support and a pay-for-performance solution that calculates and tracks clinical measures, delivering tailored intervention recommendations for patients. Through these innovative tools, MedVentive aims to facilitate meaningful improvements in healthcare outcomes and reduce overall costs.

Exact Sciences Corporation is a molecular diagnostics company based in Madison, Wisconsin, specializing in cancer screening and diagnostic tests. The company is best known for Cologuard, a non-invasive stool-based DNA test designed to detect colorectal cancer and pre-cancer, which is endorsed by leading cancer screening guidelines. Additionally, Exact Sciences offers Oncotype DX, a suite of gene expression tests that assess the recurrence risk and treatment benefits for breast and colon cancers, as well as the Oncotype DX AR-V7 Nucleus Detect test for advanced stage prostate cancer. Exact Sciences is committed to advancing its technology through research and development, focusing on enhancing the performance of Cologuard and exploring blood or fluid-based tests. The company holds exclusive intellectual property for its screening technology and has established partnerships with organizations such as the Mayo Foundation for Medical Education and Research.

Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, dedicated to developing innovative therapeutics, particularly stabilized cell-permeating alpha-helical peptides, for oncology and other therapeutic areas. The company’s lead product candidate, ALRN-6924, is designed to treat advanced solid tumors and is currently undergoing various clinical trials, including Phase 2a studies for peripheral T-cell lymphoma and advanced solid tumors, as well as Phase 1 trials for acute myeloid leukemia and myelodysplastic syndromes. Aileron Therapeutics also explores next-generation wild type p53 reactivators and has established collaborations with notable institutions such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer to evaluate the effectiveness of ALRN-6924 in combination with other treatments. Founded in 2001 and originally known as Renegade Therapeutics, the company aims to address critical cell functions through its novel approach to modulating protein-protein interactions.

BioTrove, Inc. specializes in developing and manufacturing advanced technology platforms for life science and drug discovery research. The company offers the OpenArray platform, which facilitates relative gene expression analysis and supports research across various fields such as agriculture, disease research, and public health. Additionally, BioTrove provides the RapidFire technology platform, designed for screening difficult drug targets through mass spectrometry-based assay development. This includes the RapidFire mass spectrometry hardware system, which serves as a native detection technology for drug screening and in vitro ADME applications. With a focus on high-throughput genomic analysis, BioTrove's systems enable rapid, simultaneous polymerase chain reactions (PCR) on multiple samples, thereby enhancing the efficiency of research and development processes in diverse scientific areas.

Xcellerex is a provider of manufacturing technologies specializing in biomanufacturing systems and production-scale bioreactors. Founded in 2002 in Marlborough, Massachusetts, the company focuses on transforming the production of therapeutic proteins, including biosimilars and vaccines, through innovative solutions that enhance speed and cost-efficiency. Its proprietary offerings, such as the FlexFactory®, feature modular and portable production capabilities that utilize single-use technologies and advanced process automation, allowing for faster installation and reduced contamination risks. Xcellerex also develops products like XRX-001, an inactivated virus vaccine for yellow fever, and provides a process development platform called PDMax, which supports both clinical and commercial production of biopharmaceuticals derived from mammalian, microbial, and yeast sources.

Carefx is a provider of information technology solutions for healthcare organizations in North America and Europe. Its primary offering, Fusionfx, is designed to bridge communication gaps between hospital and integrated delivery network leaders, as well as healthcare IT departments. Fusionfx synthesizes disparate data into clinically relevant, user-centric workflows, facilitating the connection of essential data points for patients, payers, clinicians, and compliance agencies. The suite includes interoperable workflow and analytics solutions that enhance both clinical and business operations, along with business intelligence dashboards that promote accountability and transparency within healthcare operations.

Skylight is a technology company specializing in interactive patient care systems for hospitals. It offers the ACCESS interactive patient system, a comprehensive two-way digital communications platform that enhances the hospital experience by transforming television sets into interactive networks for information, education, and entertainment. This system allows patients to access vital information about their care, request assistance, view health education content, and provide real-time feedback through surveys. Additionally, Skylight provides iCarePassport, a web-based system that fosters ongoing patient engagement and personalized communication throughout the care continuum. Founded in 1999 and based in San Diego, California, Skylight aims to improve health literacy and the flow of critical information between patients and caregivers.

IPC is the nation's leading national physician group practice focused on the delivery of hospital medicine and related facility-based services. IPC providers manage the care of patients in coordination with primary care physicians and specialists in over 1,100 facilities in 28 states across the U.S. We provide care to over 1 million patients annually while maintaining high standards of quality care, aligning with the mission and objectives of the facilities where we serve.

ForHealth Technologies specializes in developing automation technology solutions specifically for intravenous drug preparation. Founded in 1998 and based in Daytona Beach, Florida, the company aims to enhance the efficiency and safety of medication preparation processes. In March 2009, ForHealth Technologies was acquired by Baxa Corporation, further integrating its innovative solutions into the healthcare sector.

Passport Health Communications, Inc. is a software-as-a-service company specializing in revenue cycle management solutions for healthcare organizations, including hospitals, physician offices, and outpatient centers in the United States. The company offers a comprehensive suite of tools designed to streamline various aspects of the revenue cycle. Key products include the eCare Patient Access Suite, which facilitates patient demographic and insurance verification, compliance, and payment management; OrderChecker for validating outpatient diagnosis and procedure codes; and IntelliSource, an integrated system for patient access. Other offerings include the Patient Payment Estimator, eCashiering for processing payments, and a Claims Management Suite for claims submission and reimbursement. Passport Health Communications also provides automation solutions such as BatchSource, which enhances transaction processing. With a focus on improving efficiency and compliance, the company helps healthcare providers manage patient payments and insurance eligibility, thereby supporting effective financial operations in the healthcare sector. Founded in 1996 and headquartered in Franklin, Tennessee, the company was formerly known as InterMed, LLC before rebranding in 1998.

Virscio is a biotechnology company based in Hamden, Connecticut, focused on developing therapeutics for central nervous system disorders, including neurodegeneration, memory loss, and obesity. The company employs a predictive toxicogenomics platform called PrimaTox, which aids in the selection and pre-clinical validation of pharmaceutical candidates. In addition, Virscio provides a variety of preclinical research models and services, designed to accelerate the evaluation of therapeutic candidates. By conducting comprehensive preclinical studies and translational research programs across multiple therapeutic areas, Virscio aims to help pharmaceutical, biotechnology, and academic partners minimize the risk of clinical failure.

Emageon specializes in enterprise-level information technology solutions for the management and analysis of digital medical images within healthcare organizations. The company develops software that enables physicians and healthcare professionals to efficiently manage, access, and visualize a wide range of medical content. Its offerings include advanced visualization tools, clinical content management systems, and streamlined clinical workflows, all designed to enhance the delivery of healthcare services. Emageon's focus is on optimizing the handling of multi-specialty medical information, thereby improving patient care and operational efficiency for healthcare providers.

CareMedic Systems, Inc. is a provider of revenue cycle management solutions for hospitals and healthcare providers in the United States and Puerto Rico. Founded in 1996 and headquartered in St. Petersburg, Florida, with additional offices in Alpharetta and Decatur, Georgia, the company offers a range of products designed to optimize financial operations. Its key offerings include electronic Financial Record for healthcare financial management, VerifyAR for document management and eligibility verification, and AccelerateAR for Medicare review and claims submission. Additionally, CareMedic Systems provides OptimizeAR for payment management, ImageAR for document scanning and storage, and ResolveAR for accounts receivables outsourcing and credit balance resolution. These solutions are delivered through an application service provider model, enabling clients to streamline cash flow and improve reimbursement processes.

Zonare Medical Systems, Inc. specializes in the development, manufacturing, and commercialization of compact ultrasound systems designed for diagnostic imaging across various clinical applications. The company's flagship product, the z.one ultrasound system, leverages its proprietary Zone Sonography technology, which facilitates advanced image processing and the integration of new clinical applications. Zonare Medical operates a direct sales model in the United States and utilizes a combination of distributors and direct sales personnel in approximately 40 international markets. Established in 1999 and headquartered in Mountain View, California, Zonare Medical was formerly known as NovaSonics, Inc. The company is recognized for its patented designs and architecture that provide high-quality imaging solutions with significant clinical versatility.